A world first program designed to help medical researchers in type one diabetes develop their leadership skills to help take innovations out of the lab and into the real world has graduated its first intake. The graduates, announced in Canberra on June 26th 2018, have already put their skills into practice, securing funding to look at a dietary supplement that could stop type one diabetes. Read More
Two promising Australian research projects have been awarded almost $3 million in funding from The Leona M. and Harry B. Helmsley Charitable Trust, to be administered by JDRF Australia.
A recent study published in Diabetologia from the TrialNet group has found that the shape of the glucose curve during a glucose tolerance test predicted risk of type 1 diabetes (T1D) development. TrialNet is an international network of leading academic institutions, clinicians, scientists and healthcare teams dedicated to the prevention of T1D. Read More
A pilot clinical trial in the US has found a new immunotherapy treatment to be safe in people with new onset type 1 diabetes (T1D).
After clinical presentation of T1D, beta cell loss continues progressively in most people until C-peptide levels, a marker of endogenous insulin production, is absent or present in very low levels. Despite intensive research efforts for more than 20 years, no therapy is currently available to prevent beta cell loss in T1D.
TrialNet is an international collaborative network that aims to prevent, delay and reverse the progression of type 1 diabetes, involving United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand.
TrialNet in Australia/New Zealand is led by A/Prof John Wentworth at Walter & Eliza Hall Institute (WEHI) in collaboration with Prof Peter Colman AM.
A new study has developed a prediction tool to help clinicians predict which newly diagnosed children and adolescents are unlikely to experience a period of remission.
The remission phase, also called the honeymoon phase, is the period of time after clinical diagnosis of T1D where the body can make just enough insulin (“endogenous” insulin) to control blood glucose levels either without needing insulin injections or with significantly lower doses. Read More
A new study has found that children with type 1 diabetes (T1D) who are hospitalised for Diabetic Ketoacidosis (DKA) are more likely to develop acute kidney injury (AKI), a sudden episode of renal failure or damage. DKA is a severe complication that occurs with prolonged hyperglycaemia. It may occur at the initial presentation of newly diagnosed T1D or in someone with pre-existing T1D in times of illness or insulin omission.
There are a number of genes linked to type 1 diabetes (T1D), but not everyone with genetic predisposition develops the condition. This suggests that there are likely environmental triggers that stimulate the development of T1D. The Environmental Determinants of Diabetes in the Young (TEDDY), a study part supported by JDRF, is a large prospective, longitudinal cohort study investigating the environmental factors that may contribute to T1D development.
An article published by the TEDDY study group in Paediatric Diabetes this month highlights the benefits of early diagnosis of children at risk of T1D. Children involved in TEDDY are from six large clinical centres across the US and Europe and are being followed from birth until 15 years of age to track diet, illness, body growth and other life experiences.
A new study suggests a link between enteroviruses, and the development of type 1 diabetes (T1D). This study, part-funded by JDRF, isn’t the first to find this link but the authors say it’s the largest and most definitive study of its kind to date.
Professor Keikki HyÖty and Dr Hanna Honkanen led this study published in Diabetologia at the University of Tampere in Finland. They found that children at high risk of T1D who then go on to develop the disease, had a higher number of enterovirus infections compared to those without the disease.
Image credit: University of Pennsylvania
Infection with a common virus known as coxsackievirus B has long been thought to be associated with the development of type 1 diabetes. Now, researchers have published evidence that this virus could be driving the activity of the very genes that increase the risk of developing type 1 diabetes. Read More